Office of the Director
John A. Kitzhaber, MD, Governor

Oregon Health Authority

500 Summer Street NE E-20
Salem, OR 97301
Voice: 503-947-2340
Fax: 503-947-2341
Website: www.Oregon.Gov/OHA

OFFICIAL WEBSITE NOTICE
Posting Date: March 1, 2013

RECOMMENDATIONS OF DRUG USE REVIEW / PHARMACY AND THERAPTUETICS COMMITTEE

The Oregon Drug Use Review / Pharmacy and Therapeutics Committee met in Wilsonville, Oregon on Thursday, January 31st, 2013. The committee considered in order of priority: the safety and efficacy of the drugs being considered, the ability of Oregonians to access effective prescription drugs that are appropriate for their clinical conditions and finally, substantial differences in costs of drugs within the same therapeutic class. Based upon the clinical information presented by staff and all public comment offered, while considering the impact on special populations, the Committee makes the following recommendations for the Oregon Prescriber-Managed Prescription Drug Plan (PMPDP) or for any other preferred drug list established by the Oregon Health Authority:

Retisert

The Committee reviewed the abbreviated new drug evaluation of Retisert and as it is a surgical procedure, recommended that the Health Evidence Review Commission evaluate the line placement for the surgical procedure codes 60728 and 67027 for the fluocinolone and dexamethasone ocular implants using the provided evidence summary.

Overactive Bladder Class

The Committee reviewed the overactive bladder class update and determined that there was no new consistent evidence of benefit or safety for one product over another, but recommended that the PMPDP continue to include both ER and IR options as alternatives. Following the review of confidential pricing in executive session the Committee recommended making hyoscyamine rapid tabs preferred and to make Oscimin, hyoscyamine drops, and Gelnique non-preferred. The Committee also recommended making tolterodine non-preferred with a 90 day grandfather to transition current utilizers.

Mirabegron New Drug Evaluation

The Committee reviewed the new drug evaluation of mirabegron and due to the lack of long term clinical outcome data and direct comparative data suggesting superior efficacy or tolerability of mirabegron over currently available agents, make non-preferred.

Aclidinium Bromide

The Committee reviewed the new drug evaluation of aclidinium bromide and agreed that the evidence did not demonstrate clinical superiority of this agent over tiotropium. Following the review of confidential pricing in executive session the Committee recommended making aclidinium non-preferred.

Combivent Respimat

The Committee reviewed the abbreviated new drug evaluation of the Combivent Respimat inhaler as it will be replacing the Combivent MDI inhaler and will be the only product available as of January 1, 2014. After reviewing the clinical information the Committee evaluated the comparative costs of individual components (albuterol and ipratropium) to the combination product in executive session. The Committee recommended making Combivent Respimat and Combivent MDI non-preferred and require a step through therapy with either component (short acting beta agonist OR a short acting anticholinergic) and to grandfather current utilizers.

Macrolide Antibiotics Scan

The Committee reviewed the scan of the macrolide antibiotic class and agreed with the staff recommendation that there was insufficient evidence that consistently demonstrates the superiority of one macrolide over another and that no further research or review was needed at this time. After reviewing confidential pricing in executive session the Committee recommended making all erythromycin products non-preferred.

Fluoroquinolone Antibiotics Scan

The Committee reviewed the scan of the fluoroquinolone antibiotic class and recommended that no further class update or research was needed at this time. After reviewing confidential pricing in executive session the Committee recommended making Noroxin non-preferred.

Proton Pump Inhibitors (PPI) Scan

The Committee reviewed the scan of the PPI class and recommended that no further class update or research was needed at this time. The Committee also approved the updated prior authorization criteria. Following the review of confidential pricing in executive session the Committee recommended making omeprazole tablets non-preferred.

H2-Antagonists Scan

The Committee reviewed the scan of the H2-antagonist class and recommended that no further class update or research was needed at this time. After reviewing confidential pricing in executive session the Committee recommended making all OTC products non-preferred and to make cimetidine non-preferred and grandfather current utilizers.

Newer Antihistamines Scan

The Committee reviewed the scan of the newer antihistamine class and recommended that no further class update or research was needed at this time. After reviewing confidential pricing in executive session the Committee recommended making all OTC products non-preferred.

The Committee has made these recommendations to the Oregon Health Authority for approval by the Director of the Oregon Health Authority.

APPROVAL BY THE DIRECTOR OF THE OREGON HEATLH AUTHORITY

The recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee are approved and will be put into place no earlier than 60 days from the date this notice is posted on the web site.

Bruce Goldberg, M.D.
Director

3-1-13
Approval date

A request for reconsideration of this decision to adopt the recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee must be filed with and received by the Director no later than 30 calendar days from the date of this notice. 2011 OR law, CH 730 (HB2100) Section